Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancerYang Zhang, Amit Verma, Xiaoyi Chen et al.|Journal of Hematology & Oncology|2022Cited by 35
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependencySarah Aminov, Amit Verma, Carolina Schinke et al.|Journal of Clinical Investigation|2024Cited by 20
Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling InhibitionSarah Aminov, Amit Verma, Orsi Giricz et al.|Blood|2022Cited by 3
Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancerYang Zhang, Amit Verma, Xiaoyi Chen et al.|Journal of Hematology & Oncology|2022Cited by 1
Abstract 4820: Anti-CD72 nanobody-based CAR-T affinity maturation leads to improved in vitro efficacy versus low antigen density lymphoma models, but limited benefit in vivoAdila Izgutdina, Arun P. Wiita, Tasfia Rashid et al.|Cancer Research|2025Cited by 1